Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four antimicrobial agents: amoxicillin (a penicillin-type antibiotic), cefuroxime (a second-generation cephalosporin), clarithromycin (a macrolide antibiotic), and clavulanic acid (a beta-lactamase inhibitor that protects amoxicillin from degradation by certain bacteria). While individual components or pairs of these medications are commonly used in clinical practice, this specific four-drug combination is not a standard formulation. The individual components have different mechanisms of action against bacteria, with amoxicillin and cefuroxime targeting bacterial cell wall synthesis, clarithromycin inhibiting bacterial protein synthesis, and clavulanic acid protecting beta-lactam antibiotics from degradation by bacterial enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + cefuroxime + clarithromycin + clavulanic acid.